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Abstract Recently two point mutations in the K-synuclein gene
have been found in familial Parkinson’s disease. The character-
istic fibrous neuropathological lesions of Parkinson’s and other
neurodegenerative diseases have been shown to stain strongly
with antibodies against K-synuclein and extracted filaments have
been labelled with anti-K-synuclein antibodies. In view of the
close involvement of K-synuclein filaments with pathology, it was
important to establish an in vitro assembly system. We report
here that C-terminally truncated recombinant K-synuclein read-
ily assembles into filaments resembling those isolated from
diseased brain and suggest that truncation by proteolysis may
play a role in the pathological process.
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1. Introduction
K-Synuclein is a presynaptic protein, of presently unknown
function, found abundantly in human brain and at lower lev-
els in other tissues [1,2]. It contains 140 amino acids and has
¢ve imperfect repeats with consensus sequence KTKEGV in
the N-terminal half and a very acidic C-terminal region. The
protein is thermostable, with little or no detectable secondary
structure, and is believed to be natively unfolded [3].
Two point mutations in the K-synuclein gene have recently
been found in rare cases of familial Parkinson’s disease (PD)
(Ala53Thr [4] and Ala30Pro [5]). PD is characterised neuro-
pathologically by the presence of Lewy bodies and Lewy neu-
rites, predominantly in the substantia nigra and other subcort-
ical brain regions [6]. Lewy bodies and neurites consist of
dense cytoplasmic inclusions of ¢brous material. Abundant
Lewy bodies and Lewy neurites in cerebral cortex are also
the de¢ning features of a common late-life dementia, known
as dementia with Lewy bodies (DLB) [7]. The linkage of fam-
ilial PD to the K-synuclein gene suggested that K-synuclein
might itself form a component of Lewy bodies and neurites
both in PD and in DLB and this was demonstrated to be the
case by antibody staining at the light microscope level [8].
Subsequently, dispersed ¢laments extracted from the brains
of patients with DLB were shown by electron microscopy to
be strongly labelled by antibodies against K-synuclein [9], sug-
gesting that such ¢laments form an important component of
Lewy bodies in both diseases. Another neurodegenerative dis-
ease, known as multiple system atrophy (MSA), was also
shown to have extractable K-synuclein-containing ¢laments in
the characteristic glial cytoplasmic inclusions that constitute
the predominant pathology [10].
The pathological assembly of K-synuclein into ¢laments and
its association with a range of neurodegenerative diseases sug-
gested that it would be important to establish an in vitro
assembly system to aid study of the ¢laments. Recombinant
human K-synuclein can be e⁄ciently expressed in E. coli [2].
Besides producing proteins with the mutations reported in
familial PD, various C-terminally truncated fragments of the
wild-type protein had been generated for mapping the epi-
topes of anti-synuclein antibodies. When incubated under
suitable conditions, we observed that C-terminally truncated
proteins, particularly K-synuclein (1^120), assembled into
¢laments much more readily than the full-length wild-type
or mutated proteins. It has been reported that K-synuclein
extracted from Lewy bodies in cases with DLB is partially
truncated [11]. These observations suggest that C-terminal
truncation of K-synuclein may play a role in assembly of K-
synuclein into ¢laments in the various diseases.
2. Materials and methods
2.1. Expression and puri¢cation of recombinant wild-type, mutated or
truncated human K-synuclein
The open reading frame of human K-synuclein was subcloned into
M13. Site-directed mutagenesis was used to change Ala30 to proline or
Ala53 to threonine. Following primer extension, the mutated cDNAs
were subcloned into the bacterial expression vector pRK172. The
carboxy-terminally truncated K-synuclein (1^110), K-synuclein (1^
120) and K-synuclein (1^130) were ampli¢ed by PCR from full-length
K-synuclein (1^140) and subcloned into pRK172. All constructs were
veri¢ed by DNA sequencing. The full-length K-synuclein construct has
been described [2]. Recombinant proteins were expressed in E. coli
BL21(DE3), as described [2]. Bacterial pellets were sonicated in
50 mM Tris, pH 8.0, 0.1 mM EDTA, 0.1 mM dithiothreitol (DTT),
0.1 mM phenylmethylsulfonyl £uoride (PMSF), and centrifuged for
15 min at 15 000 rpm. 30^50% ammonium sulfate cuts of the super-
natants were applied to an S-200 Sephacryl column equilibrated in
sonication bu¡er. For full-length wild-type and mutated K-synucleins,
peak protein fractions were applied to a Mono Q column equilibrated
in sonication bu¡er, and K-synuclein eluted using a 0^500-mM NaCl
gradient. For truncated K-synucleins, peak protein fractions from an
S-200 Sephacryl column equilibrated in 50 mM MES, pH 6.25,
0.1 mM DTT, 0.1 mM PMSF, were applied to a phosphocellulose
column equilibrated in the same bu¡er. Truncated K-synucleins were
eluted by salt step elution. Immunoblot analysis was carried out with
anti-K-synuclein serum PER4 (diluted 1:1000) [9] and developed using
a Vectastain kit (Vector Laboratories, Peterborough, UK). SDS-poly-
acrylamide gels (15%) were used to monitor protein puri¢cation and
for immunoblot analysis.
2.2. Assembly of K-synuclein ¢laments and electron microscopy
Puri¢ed recombinant human K-synuclein, Ala30Pro K-synuclein,
Ala53Thr K-synuclein, K-synuclein (1^110), K-synuclein (1^120) or
K-synuclein (1^130) was incubated in 25 Wl of 30 mM MOPS,
1 mM 4-(2-aminoethyl)benzenesulfonyl £uoride (Calbiochem), pH
7.4, at 37‡C for 48 h. The K-synuclein concentrations ranged from
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5^10 mg/ml. The samples were checked by SDS-PAGE immediately
prior to microscopy to see that there had been no protein degrada-
tion.
Aliquots of assembly mixtures were placed on carbon-coated
400-mesh grids and stained with 1% lithium phosphotungstate, and
micrographs recorded at a nominal magni¢cation of U40 000 on a
Philips model EM208S microscope. Procedures for immunoelectron
microscopy were as described [12]. The primary anti-K-synuclein anti-
sera used were PER1 (raised against amino acids 11^34 of K-synuclein
[9]), diluted 1:50, or PER4 (raised against full-length recombinant
human K-synuclein [9]), diluted 1:100. After reaction with the appro-
priate secondary gold-conjugated antibody (Sigma), the grids were
stained with 1% lithium phosphotungstate.
Micrographs of ¢laments extracted from brains of cases with DLB
or MSA and labelled with anti-K-synuclein antibodies were selected
from previously published studies [9,10], to allow comparison with the
¢laments assembled in vitro.
3. Results
When the various C-terminally truncated K-synuclein con-
structs (Fig. 1A) were run on SDS-PAGE, the expected ladder
of bands was observed by Coomassie staining (Fig. 1B) and
by immunoblotting with the PER4 antiserum (Fig. 1C). In the
latter, the bands for K-synuclein (1^120) and K-synuclein (1^
110) were more weakly labelled than those for full-length
K-synuclein and K-synuclein (1^130). This suggests that
some of the stronger epitopes which the PER4 antiserum rec-
ognises are in the C-terminal region but the results also in-
dicate that PER4 can still be used to label the truncated pro-
teins.
When the full-length wild-type or mutated proteins were
incubated at 37‡C, little aggregation was seen. For the K-syn-
uclein (1^130) construct, small irregular wavey assemblies
were formed. However, for the K-synuclein (1^120) and (1^
110) constructs long regular ¢laments were produced, more
abundantly for the former than the latter (Fig. 2). The ¢la-
ments were about 6^9 nm in width and could be up to several
microns long. In some ¢laments the overall width appeared to
vary slightly along the length of the ¢lament but in general
rather little substructure could be seen, apart from some irreg-
ular long pitch helical strands in places. The ¢laments were of
very similar appearance to those found in the various K-syn-
uclein-linked neurodegenerative diseases.
The in vitro assembled K-synuclein (1^120) ¢laments were
labelled strongly by PER4 antiserum (Fig. 3A). The appear-
ance of individual ¢laments (Fig. 3B,C) was very similar to
that of PER4 labelled ¢laments extracted from brains with
DLB (Fig. 3D) or MSA (Fig. 3E). The labelling was apparent
along the whole length of the ¢lament. By contrast PER1
antiserum predominantly labelled a single end of the in vitro
assembled ¢laments (Fig. 3F^H), as has been described for
¢laments from cases of DLB or MSA (Fig. 3I). For the in
vitro assembled ¢laments, some gold particles were also seen
at the sides of ¢laments (e.g. Fig. 3G) but this is not surpris-
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Fig. 1. K-Synuclein and various C-terminally truncated constructs.
A: Diagram of the full-length 140 amino acid protein, showing re-
peats and acidic C-terminal region, together with truncated proteins
of lengths 130, 120 and 110 amino acids. B: Coomassie brilliant
blue stained blot of puri¢ed K-synuclein constructs. C: Immunoblot
with antiserum PER4 similar to that shown in B. Lanes 1: Full-
length protein; 2: 1^110; 3: 1^120; 4: 1^130.
Fig. 2. Electron micrographs of in vitro assembled ¢laments. A:
K-Synuclein (1^120); B: K-synuclein (1^110). Scale bar 100 nm.
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ing, as the ¢laments were assembled from quite high concen-
trations of K-synuclein, so unassembled molecules could well
have casually adhered to the ¢laments.
4. Discussion
Point mutations in the K-synuclein gene have been identi-
¢ed in rare cases of familial PD [4,5]. In sporadic PD and
DLB the characteristic Lewy bodies and Lewy neurites have
been shown to stain with anti-K-synuclein antibodies
[8,9,11,13^15], as have glial cytoplasmic inclusions in MSA
[10,16^18]. Furthermore, sarkosyl extracted individual ¢la-
ments with a clear morphology have also been shown to be
labelled by anti-K-synuclein antibodies in cases of DLB [9]
and MSA [10]. These observations strongly link the presence
of aggregates of abnormal K-synuclein containing ¢laments
with the neurodegenerative process in these diseases.
We show here that C-terminally truncated K-synuclein, par-
ticularly K-synuclein (1^120), assembles into ¢laments mor-
phologically very similar to those seen in the various neuro-
degenerative diseases. Additionally the pattern of labelling of
the in vitro assembled ¢laments with anti-K-synuclein anti-
bodies is very similar to that seen with ¢laments extracted
from diseased brain [9,10]. Antiserum PER4, raised against
full-length K-synuclein, decorated the whole length of ¢la-
ments, whereas PER1, raised against amino acids 11^34 of
K-synuclein, decorated only one end of the ¢laments. This
indicates that the packing of K-synuclein molecules into the
in vitro formed ¢laments is very similar to that in the ¢la-
ments extracted from brain. Under the conditions de¢ned
here, full-length K-synuclein, wild-type or mutated as in fam-
ilial PD, failed to give ¢laments.
A large proportion of the K-synuclein extracted from par-
tially puri¢ed Lewy bodies in DLB has been found to be
truncated [11]. In conjunction with the in vitro results re-
ported here, this suggests that proteolytic degradation of
K-synuclein may be an important factor in the assembly of
K-synuclein in the various neurodegenerative diseases. Viewed
in this way, the mutations in familial PD may cause partial
loss of function of K-synuclein [19], which in turn leads to a
toxic gain of function as the proteolysed K-synuclein assem-
bles into aggregates with detrimental e¡ects for the cells in
which assembly occurs. The situation may be similar to that
of tau protein in the familial frontotemporal dementias, where
mutations may lead to a partial loss of function for tau pro-
tein in its interactions with microtubules and a subsequent
toxic gain of function, as tau protein assembly leads to neuro-
degeneration [20^22].
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Fig. 3. Immunolabelling of synthetic K-synuclein (1^120) ¢laments
and ¢laments extracted from diseased brains, labelled with PER4
antiserum (A^E) and labelled with PER1 antiserum (F^I). A^C:
K-Synuclein (1^120) ¢laments showing a labelled clump and individ-
ual ¢laments. D^E: Filaments extracted from brains with di¡use
Lewy body disease (D) or multiple system atrophy (E). F^I: Fila-
ments end-labelled with PER1 antiserum, showing K-synuclein (1^
120) ¢laments (F^H) and a ¢lament from a brain with multiple sys-
tem atrophy (I). The 10-nm gold particles attached to the secondary
antibody appear as black dots. Scale bar 100 nm.
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